ÂÜÀòÂÒÂ×

Michael Hodges is a seasoned expert in the biotechnology field, currently serving as a Partner at Claris Ventures since January 2023. Holding multiple significant roles, Michael is a Board Member at AbVacc, focused on developing vaccines for emerging infectious diseases, and Resalis Therapeutics, which targets metabolic disorders through non-coding RNA. Michael is also the Chief Executive Officer of 1STRAND and participates on strategic advisory boards for several companies, including eFFECTOR Therapeutics. Previous experience includes serving as Chief Medical Officer at Amplyx Pharmaceuticals, where the focus was on antifungal agents, and at Santaris Pharmaceuticals, which was acquired by Roche. Michael's educational background includes an MB BS in Medicine from Westminster Medical School and a Bachelor of Science in Pharmacology from King's College London.